Mostrar el registro sencillo del ítem
dc.contributor.author
Gramajo, Ana Laura
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Marquez, G. E.
dc.contributor.author
Torres, Victor Eduardo Roque
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Juarez, Cecilia Paola
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Rosenstein, Ruth Estela
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.contributor.author
Luna, J. D.
dc.date.available
2017-03-16T21:21:26Z
dc.date.issued
2015-08
dc.identifier.citation
Gramajo, Ana Laura; Marquez, G. E.; Torres, Victor Eduardo Roque; Juarez, Cecilia Paola; Rosenstein, Ruth Estela; et al.; Therapeutic benefit of melatonin in refractory central serous chorioretinopathy; Nature Publishing Group; Eye; 29; 8; 8-2015; 1036-1045
dc.identifier.issn
0950-222X
dc.identifier.uri
http://hdl.handle.net/11336/14003
dc.description.abstract
PURPOSE: To evaluate the efficacy and safety of melatonin for the treatment of chronic central serous chorioretinopathy (CSCR). METHODS: Prospective comparative case series. A total of 13 patients with chronic CSCR were treated for 1 month: 8 patients were treated orally with 3 mg melatonin t.i.d., and 5 with placebo. All patients had 20/40 or worse Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) in the affected eye or presented an incapacitating scotoma. Most of the patients had previous failed treatments for their condition. Observational procedures included ETDRS BCVA, and complete ophthalmic examination. Optical coherence tomography (OCT) was performed at day 1 and week 4. Fluorescein angiography was performed at baseline only for diagnostic purposes. Data were subjected to two-sample t-test statistical analysis. P-values of <0.05 were considered statistically significant. RESULTS: At 1-month follow-up, BCVA significantly improved in 87.5% of patients treated with melatonin (7 of 8 patients, P<0.05). All patients showed a mean significant reduction (P<0.01) of central macular thickness (CMT) when compared with the baseline, with 3 patients (37.5%) exhibiting complete resolution of subretinal fluid at 1-month follow-up. No significant side effects were observed. No changes in BCVA or CMT were noted in the control group. CCONCLUSIONS: These results suggest that melatonin is safe, well tolerated, and effective in the treatment of chronic CSCR, as it significantly improved BCVA and CMT in patients with this pathology. Further evaluations with longer follow-up and a larger patient population are desirable.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Nature Publishing Group
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Central Serous Chorioretinopathy
dc.subject
Melatonin
dc.subject
Optical Coherence Tomography (Oct)
dc.subject
Fluorescein Angiography
dc.subject.classification
Oftalmología
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
Medicina Clínica
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.title
Therapeutic benefit of melatonin in refractory central serous chorioretinopathy
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2017-03-06T17:07:32Z
dc.identifier.eissn
1476-5454
dc.journal.volume
29
dc.journal.number
8
dc.journal.pagination
1036-1045
dc.journal.pais
Reino Unido
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.journal.ciudad
Londres
dc.description.fil
Fil: Gramajo, Ana Laura. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
dc.description.fil
Fil: Marquez, G. E.. Fundacion Ver; Argentina
dc.description.fil
Fil: Torres, Victor Eduardo Roque. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones y Estudio sobre Cultura y Sociedad; Argentina. Universidad Nacional de Córdoba. Facultad de Ciencias Económicas; Argentina
dc.description.fil
Fil: Juarez, Cecilia Paola. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundacion Ver; Argentina
dc.description.fil
Fil: Rosenstein, Ruth Estela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Centro de Estudios Farmacológicos y Botánicos; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental; Argentina
dc.description.fil
Fil: Luna, J. D.. Fundacion Ver; Argentina
dc.journal.title
Eye
![Se ha confirmado la validez de este valor de autoridad por un usuario](/themes/CONICETDigital/images/authority_control/invisible.gif)
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/http://www.nature.com/eye/journal/v29/n8/full/eye2015104a.html
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1038/eye.2015.104
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4541344/
Archivos asociados